Characteristics of Facilities With Early and Rapid Ustekinumab Adoption for Patients With Inflammatory Bowel Disease

Author:

Cohen-Mekelburg Shirley123ORCID,Van Tony1,Berinstein Jeffrey A.3,Yu Xianshi4,Costa Deena Kelly56,Wallace Beth I.178,Saini Sameer123,Admon Andrew J.1910,Higgins Peter D.R.3,Zhu Ji4,Waljee Akbar K.123

Affiliation:

1. VA Center for Clinical Management Research, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA;

2. Gastroenterology Service, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA;

3. Division of Gastroenterology & Hepatology, University of Michigan Medicine, Ann Arbor, Michigan, USA;

4. Department of Statistics, University of Michigan Medicine, Ann Arbor, Michigan, USA;

5. School of Nursing, Yale University, New Haven, Connecticut, USA;

6. Section on Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA;

7. Division of Rheumatology, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, Michigan, USA;

8. Rheumatology Service, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA;

9. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, Michigan, USA;

10. Pulmonary Service, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.

Abstract

INTRODUCTION: To examine which facility characteristics, including teamwork, are associated with early or rapid inflammatory bowel disease-related ustekinumab adoption. METHODS: We examined the association between ustekinumab adoption and the characteristics of 130 Veterans Affairs facilities. RESULTS: Mean ustekinumab adoption increased by 3.9% from 2016 to 2018 and was higher in urban compared with rural facilities (β = 0.03, P = 0.033) and among facilities with more teamwork (β = 0.11, P = 0.041). Compared with nonearly adopters, early adopters were more likely be high-volume facilities (46% vs 19%, P = 0.001). DISCUSSION: Facility variation in medication adoption provides an opportunity for improving inflammatory bowel disease care through targeted dissemination strategies to improve medication uptake.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3